Literature DB >> 29381784

Thymic PTH Increases After Thyroparathyroidectomy in C57BL/KaLwRij Mice.

Maurizio Zangari1, Hanna Yoo1, Ikjae Shin1, Bumjun Kim2, Ricky Edmondson1, Gareth J Morgan1, Larry J Suva3, Donghoon Yoon1.   

Abstract

We previously reported a substantial correlation between serum parathyroid hormone (PTH) levels and the myeloma response to proteasome inhibition that suggests a crucial role for the PTH receptor 1 system in the control of myeloma tumor growth. While investigating the role of PTH in the antimyeloma effect, we observed the recovery of serum PTH levels after thyroparathyroidectomy (TPTX). Although the presence of thymus-derived PTH has been reported previously, the existence or role of thymic PTH in the serum remains controversial. Here, TPTX was performed in 8- to 12-week-old C57BL/KaLwRij mice to delineate the potential source(s) for the recovery of serum PTH. Immediately after TPTX, the expected loss of measurable serum PTH was observed. Serum PTH levels recovered 3 to 4 weeks after TPTX. Thirteen endocrine organs from mice with recovered serum PTH were examined. The thymus from control mice expressed measurable and detectable Pth transcripts; however, the Pth transcript level was substantially elevated in tissue from TPTX mice. Western blot analysis of the thymus demonstrated a reproducible and distinct PTH band in thymus tissue that was significantly increased after TPTX. To directly confirm the identity of the distinct PTH band, immunoprecipitated proteins were isolated and subjected to tandem mass spectrometry. After fragmentation and direct peptide sequencing, PTH peptides PTH(1-13) and PTH(54-70), diagnostic for PTH, were identified. These data demonstrate that the murine thymus produces PTH and that after TPTX the thymus becomes the major source of serum PTH, compensating for the loss of the parathyroid glands and returning circulating PTH levels to normal.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29381784      PMCID: PMC5839736          DOI: 10.1210/en.2017-03083

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  26 in total

1.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels.

Authors:  A Shevchenko; M Wilm; O Vorm; M Mann
Journal:  Anal Chem       Date:  1996-03-01       Impact factor: 6.986

2.  Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Authors:  P I Croucher; C M Shipman; J Lippitt; M Perry; K Asosingh; A Hijzen; A C Brabbs; E J van Beek; I Holen; T M Skerry; C R Dunstan; G R Russell; B Van Camp; K Vanderkerken
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

3.  Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma.

Authors:  Deepanwita Sengupta; Stephanie D Byrum; Nathan L Avaritt; Lauren Davis; Bradley Shields; Fade Mahmoud; Matthew Reynolds; Lisa M Orr; Samuel G Mackintosh; Sara C Shalin; Alan J Tackett
Journal:  Mol Cell Proteomics       Date:  2015-11-30       Impact factor: 5.911

Review 4.  Proteasome inhibitor therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Teru Hideshima; Constantine Mitsiades; Paul Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2005-04       Impact factor: 6.261

5.  Genetic ablation of parathyroid glands reveals another source of parathyroid hormone.

Authors:  T Günther; Z F Chen; J Kim; M Priemel; J M Rueger; M Amling; J M Moseley; T J Martin; D J Anderson; G Karsenty
Journal:  Nature       Date:  2000-07-13       Impact factor: 49.962

Review 6.  Impact of bortezomib on bone health in myeloma: a review of current evidence.

Authors:  Maurizio Zangari; Evangelos Terpos; Fenghuang Zhan; Guido Tricot
Journal:  Cancer Treat Rev       Date:  2012-01-09       Impact factor: 12.111

7.  A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.

Authors:  Maurizio Zangari; Shmuel Yaccoby; Lisa Pappas; Federica Cavallo; Naveen Sanath Kumar; Subramanian Ranganathan; Larry J Suva; J Michael Gruenwald; Steven Kern; Fenghuang Zhan; Dixie Esseltine; Guido Tricot
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 8.  Multiple myeloma biology: lessons from the 5TMM models.

Authors:  Karin Vanderkerken; Kewal Asosingh; Peter Croucher; Ben Van Camp
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

9.  The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Maurizio Zangari; Shmuel Yaccoby
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047

Review 10.  Chemistry and physiology of parathyroid hormone.

Authors:  J T Potts
Journal:  Clin Endocrinol (Oxf)       Date:  1976       Impact factor: 3.478

View more
  2 in total

1.  Development of Surgically Transplantable Parathyroid Hormone-Releasing Microbeads.

Authors:  Ha Yeong Kim; Ji Min Seok; Soo Yeon Jung; Min Ji Lee; An Nguyen-Thuy Tran; Seon Ju Yeo; Su A Park; Han Su Kim
Journal:  Biomedicines       Date:  2022-02-14

Review 2.  Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.

Authors:  Maurizio Zangari; Hanna Yoo; Ik Jae Shin; Donghoon Yoon; Larry J Suva
Journal:  J Bone Oncol       Date:  2018-02-23       Impact factor: 4.072

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.